EarleC.M., KeoghE.J., WisnieswkiZ. Stan, TullochA., LordDJ., WattersG.R., GlatthaarC.: Prostaglandin E1 therapy for impotence, comparison with papaverine. J. Urol., 143, 57–59 (1990).
2.
GallmetzerJ., AufderklammJ., MahlknechtA., LungerG.: L'uso della papaverina nella diagnosi e terapia dell'impotenza erettile. Urologia, 56; 590–595 (1989).
3.
HwangT.I.S., YangC.R., WangS.J., ChangC.L., TzaiT.S., ChangC.H., WuH.C.: Impotence evaluated by the use of prostaglandin E1. J. Urol., 141, 1357–1359 (1989).
4.
IshiiN., WatanabeH., IrisawaC., KikuchiY., KubotaY., KawamuraS., SuzukiK., ChibaR., TokiwaM., ShiraiM.: Studies on male sexual impotence. Report 18: Therapeutic trial with prostaglandin E1 for organic impotence. Jap. J. Urol., 77, 954 (1986).
5.
IshiiN., WatanabeH., IrisawaC., KikuchiY., KubotaY., KawamuraS., SuzukiK., ChibaR., TokiwaM., ShiraiM.: Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence. J. Urol., 141, 323–325 (1989).
6.
PorstH.: Stellenwert von Prostaglandin E1 (PGE1) in der Diagnostik der erektilen Dysfunktion (ED) im Vergleich zu Papaverin und Papaverin/Phentolamin bei 61 Patienten mit ED. Urologe A., 27, 22–26 (1988).
7.
Romov-JssenV., TjernlundA.: Hepatotoxicity due to treatment with papaverin. N. Engl. J. Med., 24, 1333 (1969).
8.
SchramekR., DorningerM., WaldhauserM., KonecnyP., PorpaczyP.: Prostaglandin E1 in erectile dysfunction. Efficiency and incidence of priapism. Brit. J. Urol., 65, 68–71 (1990).
9.
StacklW., HasunR., MarbergerM.: Intracavernous injection of prostaglandin E1 in impotent men. J. Urol., 140; 66–68 (1988).
10.
ViragR., AdaikanP. G.: Effects of prostaglandin E1 on penile erection and erectile failure. J. Urol., 137, 1010 (1987).
11.
WaldhauserM., SchramekP.: Efficiency and side effects of prostaglandin E1 in the treatment of erectile dysfunction. J. Urol., 140, 525–527 (1988).